SABS
SAB Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.72
+0.00%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-5.9%
Return on equity
-5.4%
Return on assets
-32.7%
Return on invested capital
0.00x
Asset turnover
-$68.2M
Cash from operations
$1.13
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026